Invest
Highlights for Q2 FY22:
- Total Revenue was at Rs. 61.2 Cr
- EBITDA was at Rs. 18.9 Cr
- PAT Rs. 14.6 Cr
Commenting on the results, Mr. Kamal Aggarwal, Chairman & MD said, “We are pleased to share that we have delivered another quarter of positive performance as all our key products witnessed robust demand. We have clocked a total operating revenue of Rs 61.2 cr for the quarter. After the backward integration of P7 and P8 unit completed, the HMDS business began operating at full capacity and reported a notable figure for the quarter. On the other hand, Bromide & CMIC business continued to maintain its business momentum.
During the quarter, we were obstructed with an unfortunate external incident. Due to this external incident, GPCB had issued a closure notice which led to production loss. Although, we had 15-20 days of finish goods inventory which had been dispatched to clients on prerequisite schedule and the impact in Q2FY22 was insignificant. The same has been revoked last week and currently, all our facilities are running at full capacity. We are a Zero liquid discharge company and adhere to all best practices require as per global standard. We are a renowned and well-qualified supplier to all major pharmaceutical MNCs. Our operations have continued to operate efficiently and compliantly within the framework for the past two decades.
Expansion of P8 & P9 facilities has been completed and will be ready for a trial run from next week onwards. We expect these units to fully commercialize from Jan-22. We are also delighted to announce that we have initiated the expansion of P10 unit at the same location for other few pharma intermediate products. We are targeting this facility to come onstream by FY23. Our goal is to add more value-added solutions that will help us sustain our business while also allowing us to take new steps forward. We are well positioned to benefit from India's structural position as a leading supplier of chemical products to global MNCs."
FAQ’s on Chemcon Speciality Chemicals Ltd Shares
